Suchergebnisse - "Roeker, Lindsey E"

PubPharm (7)

1

Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma : a multicentre, single-arm, phase 2 trial

enthalten in: The Lancet. Haematology | 2021

von Soumerai, J. | Mato, A. | Dogan, A. | +43

CommentIn: Lancet Haematol. 2021 Dec;8(12):e864-e865. - PMID 34826404

2

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN) : a phase 1/2 study

enthalten in: Lancet (London, England) | 2021

von Mato, A. | Shah, N. | Jurczak, W. | +41

CommentIn: Lancet. 2021 Mar 6;397(10277):855-857. - PMID 33676615

3

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia

enthalten in: Haematologica | 2021

von Eyre, T. | Lamanna, N. | Roeker, L. | +27

4

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Mato, A. | Roeker, L. | Jacobs, R. | +51

CommentIn: Clin Cancer Res. 2020 Jul 15;26(14):3501-3502. - PMID 32366672

5

BTK Inhibitors in Cancer Patients with COVID-19 : "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte)

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Chong, E. | Roeker, L. | Shadman, M. | +3

6

Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia

enthalten in: JAMA network open | 2019

von Roeker, L. | Sarraf Yazdy, M. | Rhodes, J. | +4

7

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial

enthalten in: American journal of hematology | 2018

von Mato, A. | Roeker, L. | Allan, J. | +27

1
[1]